Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration
The DOI matches its Crossref record.
Abstract
The complement system is thought to be involved in the pathogenesis of numerous neurological diseases, although its precise role remains controversial. In this study we used orally active C5a receptor antagonists (PMX53 and PMX205) developed in our laboratories in a rat model of 3‐nitropropionic acid (3‐NP) ‐induced Huntington's disease. Administration of the C5a antagonists (10 mg/kg/day, oral) either 48 h pre‐ or 48 h post‐toxin significantly reduced body weight loss, anorexia, and behavioral and motor deficits associated with 3‐NP intoxication. Striatal lesion size, apoptosis, neutrophil infiltration, and hemorrhage were also significantly reduced in C5a antagonist‐treated rats. Immunohistochemical analysis demonstrated marked deposition of C3 and C9, and upregulation of C5a receptors on neuronal cells at the time of lesion formation. Inhibition of prostaglandins or TNF‐α with ibuprofen or infliximab had no effect in this model. The C5a antagonists did not affect 3‐NP‐induced cell death when added directly to rat striatal neuronal cultures, indicating a secondary mechanism of action in vivo . Our findings demonstrate for the first time that complement activation in the brain, particularly C5a, is a key event in the pathogenesis of this disease model, and suggest a future role for inhibitors of C5a in the treatment of neurodegenerative diseases.—Woodruff, T. M., Crane, J. W., Proctor, L. M., Buller, K. M., Shek, A. B., de Vos, K., Pollitt, S., Williams, H. M., Shiels, I. A., Monk, P. N., Taylor, S. M. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J. 20, 1407–1417 (2006)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The role of the anaphylatoxins in health and disease
Klos, A., Tenner, A. J., Johswich, K.-O., Ager, R. R., Reis, E. S., & Köhl, J. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.04.027 · Cited by 730
Beck, K. D., Nguyen, H. X., Galvan, M. D., Salazar, D. L., Woodruff, T. M., & Anderson, A. J. (2010) · Brain · doi:10.1093/brain/awp322 · Cited by 646
Self-citationT helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 + T cells
Arbore, G., West, E. E., Spolski, R., Robertson, A. A. B., Klos, A., Rheinheimer, C., Dutow, P., Woodruff, T. M., Yu, Z. X., O’Neill, L. A., et al. (2016) · Science · doi:10.1126/science.aad1210 · Cited by 513
Self-citationComplement-targeted therapeutics
Ricklin, D., & Lambris, J. D. (2007) · Nature Biotechnology · doi:10.1038/nbt1342 · Cited by 481
Complement, a target for therapy in inflammatory and degenerative diseases
Morgan, B. P., & Harris, C. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4657 · Cited by 431
Metadata
- Authors
- Woodruff, T. M., Crane, J. W., Proctor, L. M., Buller, K. M., Shek, A. B., De Vos, K., Pollitt, S., Williams, H. M., Shiels, I. A., Monk, P. N., & Taylor, A. S. M.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2006-07
- Volume
- 20
- Issue
- 9
- Pages
- 1407-1417
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2108893725
- Cited by
- 154
- References
- 0
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. https://app.cochat.ai/papers/10.1096/fj.05-5814com
- The paper
- Woodruff, T. M., Crane, J. W., Proctor, L. M., Buller, K. M., Shek, A. B., De Vos, K., Pollitt, S., Williams, H. M., Shiels, I. A., Monk, P. N., & Taylor, A. S. M. (2006). Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. The FASEB Journal. https://doi.org/10.1096/fj.05-5814com
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.